HOME >> BIOLOGY >> NEWS
Pharmaceutical 'smart bomb' targets cancer cells

NEW BRUNSWICK/PISCATAWAY, N.J. Rutgers pharmaceutical chemist Longqin Hu and his colleagues have developed a new series of compounds for drugs that have the potential to attack cancer like a high-tech "smart bomb." This high-powered combination of a novel cell-killing agent and a precision targeting technology proved to be as much as 100 times more potent than a comparable drug currently in clinical trials.

"We are testing this combination and it looks like a winner," said Hu, an assistant professor at the Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey.

The delivery of the compound is accomplished with a prodrug an inert chemical derivative of a drug that can be activated once it reaches its destination inside a patient's body. Prodrugs can transport highly potent medicines such as Hu's cytotoxins (cell-killers), without impacting other body tissues along the way. Hu's research employs a new and improved prodrug package developed by collaborators in England.

This dramatic step in the march toward a cancer cure will be featured twice during the 226th American Chemical Society (ACS) national meeting in New York. Hu is presenting a paper on Monday, Sept. 8 at 3:45 p.m. in the Javits Convention Center, room 1E02. In addition, Hu and his colleagues are exhibiting at a poster session on Wednesday, Sept. 10 in the Hilton New York, Americas Hall 1 from 6 p.m. to 8 p.m.

Traditional anticancer drugs use accelerated cell growth as their trigger, which can produce collateral damage in rapidly replicating normal cells. "That is how you wind up with the negative side effects you see in chemotherapy patients, such as hair loss, nausea and reduced immunities," said Hu.

Instead of hitting all cells that grow fast, the newly reformulated prodrugs use a protein or enzyme as the activating trigger, guaranteeing a direct hit on cancerous cells. Nitroreductase an enzyme not normally found in the body, not
'"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 Ext. 652
Rutgers, the State University of New Jersey
31-Dec-2000


Page: 1 2

Related biology news :

1. Warren Pharmaceuticals publishes results of preclinical evaluation
2. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies
3. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
4. Pharmaceutical and personal care products: What happens when they enter the environment - an emerging concern
5. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
6. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
7. Idun Pharmaceuticals Identifies Cell Type And Molecular Pathway Involved In TransplantationRelated Liver Damage
8. Cubist Pharmaceuticals Describes New VITA™ Technology For Enabling Genomics For Drug Discovery
9. Vertex Pharmaceuticals/Yale Research Team Uses Gene Knockout Mice To Establish Role Of Caspase-9 In Neuronal Cell Death Pathway
10. Micro-Plants Yield Pharmaceutical New Wave
11. Scientists At The Scripps Research Institute And R.W. Johnson Pharmaceuticals Develop New Antibacterial Agents

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pharmaceutical smart bomb targets cancer cells

(Date:4/17/2014)... hydrogen sulfide in order to properly multiply and form ... Center for Craniofacial Molecular Biology at the Herman Ostrow ... principal investigator on the project, said the presence of ... of calcium ions. The essential ions activate a chain ... creation of new bone tissue, and keeps the breakdown ...
(Date:4/17/2014)... Singh Thursday as a "Champion of Change" for ... in the residential, commercial and industrial sectors. , ... and Computer Engineering and director of Clemson,s Center ... leading the charge across the country to create ... driving policy changes at the local level to ...
(Date:4/17/2014)... parasites and pathogens that devastate honeybees in Europe, Asia ... but do not appear to be impacting native honeybee ... of researchers., The invasive pests include including Nosema ... African honeybees appear to be resilient to these invasive ... to control pests in Europe, Asia and the United ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
(Date:1/15/2014)... , January 15, 2014 A study ... races on the Formula 1 track could help to tackle ... Applied Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) ... healthcare provider Simplyhealth. Telemetry technology, which is inspired ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2
Cached News: